Is MS an inflammatory or primary degenerative disease?

Journal of Neural Transmission

Volumn 120, Issue 10, 2013, Pages 1459-1462

  Losy, Jacek ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Autoimmunity; Chemokines; Cytokines; Inflammation; Multiple sclerosis; Neurodegeneration

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BETA INTERFERON; BETA1A INTERFERON; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DACLIZUMAB; FINGOLIMOD; INTEGRIN; NATALIZUMAB; RITUXIMAB;

ANTIGEN PRESENTING CELL; ARTICLE; AXONAL INJURY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; DEGENERATIVE DISEASE; DEMYELINATION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; LEUKOCYTE; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE DEGENERATION; NERVE FIBER; NERVOUS SYSTEM INFLAMMATION; PLASMA CELL; PRIMARY DEGENERATIVE DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION;

EID: 84885422692     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1079-9     Document Type: Article

References (30)

1. Barun B, Bar-Or A (2012) Treatment of multiple sclerosis with Anti-CD20 antobodies. Clin Immunol 142:31-37
2. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W (2002) Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123:1174-1183
3. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E (2009) Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132:3329-3341
4. Comabella M, Khoury SJ (2012) Immunopathogenesis of multiple saclerosis. Clin Immunol 142:2-8
5. Droogan A, McMillan SA (1996) Serum and CSF levels of soluble adhesion molecules in MS: predominant intrathecal release of VCAM-1. J Neuroimmunol 64:185-191
6. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175-1189
7. Hartung HP, Michels M, Reiners K (1993) Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 43:2331-2335
8. Hartung H, Reiners K, Archelos J (1995) Circulating adhesion molecules and tumour necrosis factor receptor in multiple sclerosis. Correlation with magnetic resonance imaging. Ann Neurol 38:186-193
9. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2009) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688
10. Helgeland PT, Gilhus N (2012) Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur Neurol 67:121-128
11. Infante-Duarte C, Weber A, Kratzschmar J, Prozorovski Y, Pikol S, Hamann I, Belimann-Strobl J, Aktas O, Door J, Wuerfel J (2005) Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 19:1902-1904
12. Kappos L, Antel J, Comi G, Montalban X, O' Connor P, Polman CH, Haas T, Korn A, Karlsson G, Radue E (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124-1140
13. Korn T, Bettelli E, Oukka M, Kuchroo V (2009) IL-17 and Th17 cells. Rev Immunol 27:485-517
14. Krumbholtz M, Theil D, Cepok S (2006) Chemokines in multiple sclerosis:CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 29:200-211
15. Kuenz B, Lutterotti A, Khalil M, Ehling R, Gneiss C, Deisenhammer F, Reindl M, Berger T (2005) Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sEselectin are associated with relapsing-remitting disease course of multiple sclerosis. J Neuroimmunol 167:143-149
16. Kutzeinigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-2712
17. Lassmann H (2010) What drives disease in multiple sclerosis: inflammation or neurodegeneration. Clin Exp Neuroimmunol 1:2-11
18. Lee DH, Linker RA, Gold R (2008) Spotlight on fumarates. Int MS J 15:12-18
19. Liao JJ, Huang MC, Goetzl EJ (2007) Cutting edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol 178:5425-5428
20. Losy J (1999) Adhesion molecules as surrogate marker of disease activity in multiple sclerosis. Cent Eur J Immunol 24:229-232
21. Losy J, Niezgoda A (2001) IL-18 in patients with multiple sclerosis. Acta Neurol Scand 104:171-173
22. Losy J, Niezgoda A, Wender M (1999) Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions. J Neuroimmunol 99:169-172
23. Melzer N, Meuth SG, Wiendl H (2009) CD8+ T cells and neuronal damage: direct and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J 23:3659-3673
24. O' Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R (2006) A phase II study of the safety and efficacy of teriflunomide in ultiple sclerosis with relapses. Neurology 66:894-900
25. Polman Ch, O' Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Philips T, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara M, Sandrock A (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
26. Rubenko-Moll NM, LiPing L, Cardona A, Ransohoff RM (2006) Chemokines, mononuclear cells and the nervous system: heaven or hell is in the details. Curr Opin Immunol 18:683-689
27. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T-cell in patients with multiple sclerosis. J Exp Med 199:971-979
28. Weiner H (2009) The challenge of multiple sclerosis: How do we cure a chronic heterogenous disease? Ann Neurol 65:239-248
29. Woodfin A, Voisin MB, Nourdharagh S (2007) PECAM-1: a multi-functional molecule in inflammation and vascular biology. Atheroscler Thromb Vasc Biol 27:2514-2523
30. Wynn D, Kaufman M, Mantelban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9:381-390